Read by QxMD icon Read

Acute Myelogenic Leukemia

Noha A S Al-Otaibi, Juliana S Cassoli, Nigel K H Slater, Hassan Rahmoune
The use of human leukemic (HL)-60 cells is important for studies of acute myeloid leukemia (AML) and as a model system for investigating how specific types of blood cells are formed during the process of hematopoiesis. Here, we present a protocol for growth of HL-60 cells along with molecular and functional profiles associated with their cryostorage. We also elucidate the effects of these procedures on cell viability and functions. This method can be used to provide biomarkers as readouts for testing the efficacy and/or toxicity of novel compounds in AML research as well as in a number of other experimental manipulations...
2019: Methods in Molecular Biology
Rajab Mardani, Mohammad Hassan Jafari Najaf Abadi, Mahsa Motieian, Sima Taghizadeh-Boroujeni, Amir Bayat, Alireza Farsinezhad, Seyed Mohammad Gheibi Hayat, Mahtab Motieian, Hossein Pourghadamyari
Leukemia is known as a progressive malignant disease, which destroys the blood-forming organs and results in adverse effects on the proliferation and development of leukocytes and their precursors in the blood and bone marrow. There are four main classes of leukemia including acute leukemia, chronic leukemia, myelogenous leukemia, and lymphocytic leukemia. Given that a variety of internal and external factors could be associated with the initiation and progression of different types of leukemia. One of the important factors is epigenetic regulators such as microRNAs (miRNAs) and long noncoding RNAs (ncRNA)...
December 4, 2018: Journal of Cellular Physiology
Grant Howell, Caspian Oliai, Gary Schiller
BACKGROUND: Liposomal formulation of anthracyclines provide better systemic and organ-specific tolerance, with potential for less local tissue damage during extravasation. Several small series have reported that most liposomal anthracycline extravasations are consistent with irritant injury without tissue necrosis. There have been no reports published regarding the clinical effects of extravasation of liposomal cytarabine-daunorubicin (CPX-351). CASE REPORT: The patient received CPX-351 for relapsed acute myelogenous leukemia via a left chest wall port-a-catheter...
December 2018: Anticancer Research
Meng Lv, Y U Wang, Ying-Jun Chang, Xiao-Hui Zhang, Lan-Ping Xu, Qian Jiang, Hao Jiang, Jin Lu, Huan Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Yao Chen, Chen-Hua Yan, Yuanyuan Zhang, Yuqian Sun, Xiao-Dong Mo, HongHu Zhu, Jin-Song Jia, Ting Zhao, Jing Wang, Kaiyan Liu, Xiao-Jun Huang
PURPOSE: Although myeloablative human leukocyte antigen (HLA) haploidentical hematopoietic stem cell transplantation (haplo-HSCT) following pretransplant ATG and granulocyte colony-stimulating factor (G-CSF) stimulated grafts (ATG+G-CSF) has been confirmed as an alternative to HSCT from HLA-matched sibling donors(MSDs), the effect of haplo-HSCT on postremission treatment of patients with AML with intermediate risk (int-risk AML) who achieved first complete remission (CR1) has not been defined...
November 26, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Clyde D Ford Md, Bert K Lopansri Md, Brandon J Webb Md, Jana Coombs Bs, Launce Gouw Md, Julie Asch Md, Daanish Hoda Md
BACKGROUND: The frequency, risk factors, and outcomes for Clostridioides difficile infection (CDI) in patients with newly diagnosed acute leukemia (AL) admitted for induction therapy are unclear. METHODS: We studied 509 consecutive patients with AL admitted between 2006 and 2017 and conducted a prospective C difficile surveillance and ribotyping analysis in a subset of these. RESULTS: The incidence of CDI was 2.2/1,000 inpatient days during induction, and CDI was rare after discharge...
November 21, 2018: American Journal of Infection Control
Tania Jain, Fares Alahdab, Belal Firwana, Mohamad Bassam Sonbol, Diana Almader-Douglas, Jeanne Palmer
Fludarabine with busulfan (FB) or melphalan (FM) are two more commonly used reduced intensity conditioning regimens for allogeneic stem cell transplantation (HCT).We present a systematic review and meta-analysis of studies comparing these two RIC regimens. We searched electronic databases from inception through November 1st , 2017 for literature search to identify relevant studies. DerSimonian random effects model was used to measure efficacy outcomes; hazard ratios and corresponding 95% confidence interval are reported...
November 21, 2018: Biology of Blood and Marrow Transplantation
Karolina Kró Lewska-Goliñska, Marcin J Cieślak, Milena Sobczak, Rafał Dolot, Ewa Radzikowska-Cieciura, Mariola Napiórkowska, Iwona Wybrañska, Barbara Nawrot
BACKGROUND: Novel derivatives of benzo[b]furan were found to be highly toxic towards human chronic myelogenous (K562), acute myelogenous (HL-60) and acute lymphoblastic (MOLT-4) leukemia cells. OBJECTIVE: Characterization of the biological activity of novel benzofurans (influence on apoptosis, mitogen activated protein kinases and on the cell cycle). Identification of cellular protein(s) targeted by test benzofurans and defining the mechanism of action. METHOD: chemical synthesis, fluorescence assays, flow cytometry, gene expression by DNA microarray and real time RT-PCR, western blotting, cytotoxicity assays, pull-down assay, mass spectroscopy, in vitro polymerization of tubulin, molecular docking...
November 22, 2018: Anti-cancer Agents in Medicinal Chemistry
Runxia Gu, Xue Yang, Hui Wei
For decades, genetic aberrations including chromosome and molecular abnormalities are important diagnostic and prognostic factors in acute myeloid leukemia (AML). ATRA and imatinib have been successfully used in AML and chronic myelogenous leukemia, which proved that targeted therapy by identifying molecular lesions could improve leukemia outcomes. Recent advances in next generation sequencing have revealed molecular landscape of AML, presenting us with many molecular abnormalities. The individual prognostic information derived from a specific mutation could be modified by other molecular lesions...
2018: Biomarker Research
Dubayová Katarína, Kožlejová Zuzana, Vašková Judita, Čakanová Gladys, Kiktavá Mária, Guman Tomáš, Sabo Ján, Karabinos Anton
BACKGROUND: The study investigated FLT3 gene mutations in patients from eastern Slovakia using a simple molecular method. PATIENTS AND METHODS: We analyzed 141 patients with primary acute myeloid leukemia (AML) and 8 patients with AML that developed from myelodysplastic syndrome (MDS) who were aged 19-81 years. DNA isolated from peripheral blood and/or bone marrow was analyzed by PCR. FLT3 internal tandem duplication (FLT3-ITD) was detected by amplification of exons 14 and 15...
2018: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
Francesca Musumeci, Chiara Greco, Giancarlo Grossi, Alessio Molinari, Silvia Schenone
Ponatinib is a third line drug for the treatment of chronic myeloid leukemia patients, especially those that develop the gatekeeper mutation T315I, which is resistant to the first and the second line drugs imatinib, nilotinib, dasatinib and bosutinib. The compound was first identified as a pan Bcr-Abl and Src kinase inhibitor. Further studies have indicated that it is a multitargeted inhibitor that is active on FGFRs, RET, AKT, ERK1/2, KIT, MEKK2 and other kinases. For this reason, the compound has been evaluated on several cancers in which these kinases play important roles, including thyroid, breast, ovary and lung cancer, neuroblastoma, rhabdoid tumours and in myeloproliferative disorders...
November 9, 2018: Cancers
Husnain Waseem, Carlos Henriquez Felipe, Arsalan Talib Hashmi, Maham Ansar, Asiya Batool, Angela Saverimuthu, Stephan L Kamholz
No abstract text is available yet for this article.
November 8, 2018: American Journal of Therapeutics
Ryoji Kobayashi, Daiki Hori, Hirozumi Sano, Daisuke Suzuki, Kenji Kishimoto, Kunihiko Kobayashi
Infection, especially invasive fungal infection (IFI), is an important complication of chemotherapy and stem cell transplantation. It is also a well-known risk factor in pediatric hematologic malignancy, acute myelogenous leukemia, recurrent disease and allogeneic stem cell transplantation. We previously revealed that a diagnosis of acute myelogenous leukemia, recurrent disease and >10 years of age were risk factors for IFI in patients with pediatric hematologic malignancies. We examined and compared the incidence, risk factors and mortality rate from IFI between 276 patients from 2007 to 2016 and patients in our past report...
December 2018: Pediatric Infectious Disease Journal
Takashi Yamamichi, Hirotoshi Horio, Ayaka Asakawa, Masayuki Okui, Masahiko Harada
Background: The complication rate of fungal disease is higher among patients with hematological malignancies. We investigated the clinicobacteriological outcomes of resected pulmonary fungal infections complicating hematological malignancies. Methods: Between 2001 and 2017, 21 patients with pulmonary fungal infections complicating hematological malignancies underwent resection, and their clinical records and survival were retrospectively reviewed. Results: The median age of the patients was 47 years, and 13 were male...
October 2018: Korean Journal of Thoracic and Cardiovascular Surgery
Xinning Zhang, Mengqiu Song, Joydeb Kumar Kundu, Mee-Hyun Lee, Zhen-Zhen Liu
PIM (proviral integration site for moloney murine leukemia virus) kinase plays a key role as an oncogene in various cancers including myeloma, leukemia, prostate and breast cancers. The aberrant expression and/or activation of PIM kinases in various cancers follow an isoform-specific pattern. While PIM1 is predominantly expressed in hematological and solid tumors, PIM2 and PIM3 are largely expressed in leukemia and solid tumors, respectively. All of PIM kinases cause transcriptional activation of genes involved in cell survival and cell cycle progression in cancer...
September 2018: Journal of Cancer Prevention
Gunnar Birgegård, Folke Folkvaljon, Hans Garmo, Lars Holmberg, Carlos Besses, Martin Griesshammer, Luigi Gugliotta, Jingyang Wu, Heinrich Achenbach, Jean-Jacques Kiladjian, Claire N Harrison
EXELS, a post-marketing observational study, is the largest prospective study of high-risk essential thrombocythemia (ET) patients, with an observation time of 5 years. EXELS found higher event rates of acute leukemia transformation in patients treated with hydroxycarbamide (HC). In the current analysis, we report age-adjusted rates of malignant transformation from 3460 EXELS patients exposed to HC, anagrelide (ANA), or both. At registration, 481 patients had ANA treatment without HC exposure, 2305 had HC without ANA exposure, and 674 had been exposed to both...
November 2018: Leukemia Research
Pradyumna Agasthi, Hemalatha Narayanasamy, Dan Sorajja, James Slack, Farouk Mookadam
Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes, chronic myelogenous leukemia, and acute myelogenous leukemia. We present a case of cardiomyopathy associated with decitabine used for secondary acute myelogenous leukemia. The patient presented with new heart failure symptoms and an ejection fraction decline.
2018: Case Reports in Cardiology
Chelsea K Meenan, John A Kelly, Li Wang, A Kim Ritchey, Scott H Maurer
PURPOSE: Obesity correlates with adverse events (AEs) in children with acute myelogenous leukemia and during maintenance therapy for acute lymphoblastic leukemia (ALL). Less is known about AEs in obese ALL patients during pre-maintenance chemotherapy. We evaluated the relationship between obesity (body mass index (BMI) ≥ 95th percentile) and AEs during pre-maintenance chemotherapy in pediatric patients with ALL. METHODS: One hundred fifty-five pediatric ALL patients diagnosed at a single institution between 2006 and 2012 were retrospectively evaluated for infections, treatment-requiring hypertension, insulin-requiring hyperglycemia, pancreatitis, pediatric intensive care unit admissions, sepsis, febrile neutropenia (FN) admissions, thrombosis, hepatotoxicity, and nephrotoxicity...
October 26, 2018: Pediatric Blood & Cancer
Rebecca Levin-Epstein, Caspian Oliai, Gary Schiller
Acute myelogenous leukemia (AML) in the elderly is complex and has a poor prognosis, often characterized by higher risk cytogenetic and molecular features compared to that in younger patients. Rates of transplant have been limited by concern related to non-relapse mortality, as older patients have historically been considered medically unfit for the transplantation process. Reduced-intensity conditioning (RIC) for hematopoietic stem cell transplantation (HSCT) has been shown to provide similar efficacy to myeloablative methods, with decreased non-relapse mortality in the elderly and improved efficacy over non-transplant approaches with cytotoxic chemotherapy alone...
October 25, 2018: Current Treatment Options in Oncology
Rashi Khemka, Monica Gupta, Nehar Kanta Jena
Chronic myelogenous leukemia (CML) is a chronic myeloproliferative neoplasm consistently associated with the BCR-ABL1 fusion gene located in the Philadelphia chromosome. The Blast Phase is diagnosed when blasts are ≥20% of the peripheral blood white cell count or of bone marrow nucleated cells or when there is an extramedullary blast proliferation. Megakaryocytic blast crisis as the presenting manifestation of CML is extremely rare and only 7 reported cases were found in the literature. Out of 34 cases of CML-Blast Phase between April 2015 and June 2016, 3 cases showed megakaryocytic differentiation...
October 25, 2018: Pathology Oncology Research: POR
Matthew Carnevale, John Phair, Patricia Yau, Karan Garg
The link between coagulatory dysfunction in acute leukemias is well known, with patients having an increased risk of bleeding as well as thrombosis. Arterial thrombosis is particularly rare in this population however with only a few reported cases in the literature. We report the case of acute arterial occlusion secondary to a leukoblastic embolus causing limb threatening ischemia in a patient with acute myelogenous leukemia. The patient was successfully treated surgically by open superficial femoral artery thrombectomy, common femoral endarterectomy with patch angioplasty, and percutaneous tibial embolectomy...
October 17, 2018: Annals of Vascular Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"